EFFICACY, SAFETY, AND TOLERABILITY OF PRAVASTATIN FOR THE LONG-TERM TREATMENT OF PATIENTS WITH DIVERSE TYPES OF HYPERLIPIDEMIA: A MULTICENTER PROSPECTIVE STUDY

Abstract This multicenter study evaluated the efficacy, safety, and tolerability of pravastatin in the long-term treatment of patients with diverse types of primary hyperlipidemia. Of 103 patients from 21 centers, 59, 39, and 5 patients were judged to have type IIa, IIb, and IV hyperlipidemia, respectively. Patients followed an isocaloric diet throughout the trial. After a 4-week placebo period, treatment with pravastatin was initiated at 10 mg/day; the daily dose was increased to 20 mg after 4 weeks if the goal total cholesterol value (